Drugs For Benign Prostatic Hypertrophy Market trends, Top Companies, Share, Growth And Forecast 2033

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The Business Research Company's Drugs For Benign Prostatic hypertrophy Global Market Report 2024 identifies the rising male geriatric population as the major driver for the drugs for benign prostatic hypertrophy market's growth in the forecast period. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia affects around 50% of men aged between 51 and 60 years and up to 90% of men aged over 80 years.

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.02 billion in 2023 to $4.31 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.45 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.

Download Free Sample Of Drugs For Benign Prostatic hypertrophy Market Report - https://www.thebusinessresearchcompany.com/sample_request?id=2594&type=smp

Major competitors in the drugs for benign prostatic hypertrophy market areAllergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, Æterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

A key trend in the drugs for benign prostatic hypertrophy market includes technological advancement. Major companies operating in the drugs for benign prostatic hypertrophy market are increasing their focus on introducing novel medicines such as Entadfi to maximize revenue in the market. Entadfi is a prescription medicine used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate. For instance, in December 2021, Veru Inc., a US-based biotechnology company, received approval from the United States Food and Drug Administration (FDA) for Entadfi, a prescription medicine used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate for up to 26 weeks. The approval of Entadfi was based on a randomized, double-blind, placebo-controlled phase 3 study that evaluated the efficacy and safety of tadalafil plus finasteride in 696 men. Entadfi is supplied as a capsule containing a combination of finasteride 5mg and tadalafil 5mg in 30- or 90-count bottles.

Read More On The Global Drugs For Benign Prostatic hypertrophy Market Report Here:
https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

The drugs for benign prostatic hypertrophy market is segmented -
• By Type: Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types
• By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• By End User: Hospital Pharmacies, Retail Pharmacies, Other End-Users
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the drugs for benign prostatic hypertrophy market.

The Business Research Company's "Global Drugs For Benign Prostatic hypertrophy Market Report 2024" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Drugs For Benign Prostatic hypertrophy Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2594

The Table Of Content For The Drugs For Benign Prostatic hypertrophy Market Include:
1. Executive Summary
2. Drugs For Benign Prostatic hypertrophy Market Characteristics
3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies
4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario
5. Global Drugs For Benign Prostatic hypertrophy Market Size and Growth
……
31. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking
32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market
34. Drugs For Benign Prostatic hypertrophy Market Future Outlook and Potential Analysis
35. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.